ArticleIndian dermatology online journal2025
Mucocutaneous Manifestations of Leukemias and Lymphomas: A Clinical Study from a Tertiary Care Center in North India.
Article in Indian dermatology online journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMucocutaneous manifestations are common in hematological malignancies, but are generally misinterpreted. About two-thirds of the patients with hematological malignancies have mucocutaneous manifestations. Specific manifestations include leukemia cutis, leukemic vasculitis, and mucosal hyperplasia. Non-specific manifestations include reactive dermatoses, infective dermatoses, and miscellaneous manifestations. Mucocutaneous manifestations help in depicting the course and prognosis of hematological malignancies. AIM AND
objectivesTo determine the frequency and pattern of mucocutaneous manifestations in patients with leukemia and lymphoma, and to determine the degree of correlation between various mucocutaneous manifestations and the types of leukemias and lymphomas. PATIENTS AND
methodsThis cross-sectional study was conducted in hematology and dermatology outpatient and inpatient departments in a tertiary care center in North India for 18 months. The study included 177 newly diagnosed leukemia and lymphoma patients who had not undergone chemotherapy.
resultsMucocutaneous manifestations were noted in 87.57% of patients, with specific manifestations in 5.08% (gingival hyperplasia = 3.39%, leukemic vasculitis = 1.13%, leukemia cutis = 0.56%) and non-specific manifestations in 87.01% (reactive dermatoses = 4.52%, infective dermatoses = 30.5%, miscellaneous = 76.27%). Acute myeloid leukemia (AML) showed the highest frequency (96.88%) of mucocutaneous involvement. AML was significantly associated with pallor ( P value <0.001), thrombocytopenic purpura ( P value <0.001), xerosis ( P value = 0.023), and bacterial infections ( P value = 0.028). LIMITATIONS: A small sample size and a cross-sectional design, that precluded the correlation between course of muco- cutaneous manifestations and disease progression.
conclusionMucocutaneous manifestations are common in acute leukemias, particularly myeloid lineage, due to bone-marrow suppression, immune dysregulation, and cutaneous spread. B-cell neoplasms show a higher propensity for skin involvement and paraneoplastic phenomena due to their aggressive nature compared to T-cell neoplasms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.